References
1. Park MS, Chung KY, Kim KD, Yang WI, Chung JH, Kim YS et al. Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. The Annals of thoracic surgery. 2004;78(3):992-7; discussion 7-8. doi:10.1016/j.athoracsur.2004.03.097.
2. Harizi C, El-Awa F, Ghedira H, Audera-Lopez C, Fakhfakh R. Implementation of the WHO Framework Convention on Tobacco Control in Tunisia: Progress and challenges. Tobacco prevention & cessation. 2020;6:72. doi:10.18332/tpc/130476.
3. WHO. Leading cause of death, illness and impoverishment. 2020.https://www.who.int/news-room/fact-sheets/detail/tobacco .
4. Suliankatchi Abdulkader R, Sinha DN, Jeyashree K, Rath R, Gupta PC, Kannan S et al. Trends in tobacco consumption in India 1987-2016: impact of the World Health Organization Framework Convention on Tobacco Control. Int J Public Health. 2019;64(6):841-51. doi:10.1007/s00038-019-01252-x.
5. WHO. Tobacco smoking. 2018.https://apps.who.int/gho/data/node.sdg.3-a-viz?lang=en .
6. Rehm J, Anderson P, Barry J, Dimitrov P, Elekes Z, Feijão F et al. Prevalence of and potential influencing factors for alcohol dependence in Europe. European addiction research. 2015;21(1):6-18. doi:10.1159/000365284.
7. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757-66. doi:10.1001/jamapsychiatry.2015.0584.
8. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of general psychiatry. 2007;64(7):830-42. doi:10.1001/archpsyc.64.7.830.
9. Witkiewitz K. Predictors of heavy drinking during and following treatment. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 2011;25(3):426-38. doi:10.1037/a0022889.
10. Durazzo TC, Meyerhoff DJ. Psychiatric, Demographic, and Brain Morphological Predictors of Relapse After Treatment for an Alcohol Use Disorder. Alcoholism, clinical and experimental research. 2017;41(1):107-16. doi:10.1111/acer.13267.
11. Kirshenbaum AP, Olsen DM, Bickel WK. A quantitative review of the ubiquitous relapse curve. Journal of substance abuse treatment. 2009;36(1):8-17. doi:10.1016/j.jsat.2008.04.001.
12. Seo S, Mohr J, Beck A, Wüstenberg T, Heinz A, Obermayer K. Predicting the future relapse of alcohol-dependent patients from structural and functional brain images. Addiction biology. 2015;20(6):1042-55. doi:10.1111/adb.12302.
13. Nguyen LC, Durazzo TC, Dwyer CL, Rauch AA, Humphreys K, Williams LM et al. Predicting relapse after alcohol use disorder treatment in a high-risk cohort: The roles of anhedonia and smoking. J Psychiatr Res. 2020;126:1-7. doi:10.1016/j.jpsychires.2020.04.003.
14. Chiappetta V, García-Rodríguez O, Jin CJ, Secades-Villa R, Blanco C. Predictors of quit attempts and successful quit attempts among individuals with alcohol use disorders in a nationally representative sample. Drug Alcohol Depend. 2014;141:138-44. doi:10.1016/j.drugalcdep.2014.05.019.
15. McKee SA, Harrison EL, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biological psychiatry. 2009;66(2):185-90. doi:10.1016/j.biopsych.2009.01.029.
16. Skinner MD, Lahmek P, Pham H, Aubin H-J. Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis. Plos One. 2014;9(2). doi:10.1371/journal.pone.0087366.
17. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism. 2001;36(6):544-52. doi:10.1093/alcalc/36.6.544.
18. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug and Alcohol Dependence. 2009;105(1-2):33-41. doi:10.1016/j.drugalcdep.2009.05.025.
19. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. American journal of preventive medicine. 2008;35(2):158-76. doi:10.1016/j.amepre.2008.04.009.
20. Zawertailo L, Ivanova A, Ng G, Le Foll B, Selby P. Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder: A Pilot, Randomized Placebo-Controlled Trial. J Clin Psychopharmacol. 2020;40(2):130-6. doi:10.1097/JCP.0000000000001172.
21. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane database of systematic reviews. 2019;10:Ed000142. doi:10.1002/14651858.Ed000142.
22. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2011;343:d5928. doi:10.1136/bmj.d5928.
23. Bei P, Long G, Yang-Qin X, Ya-Jing C, Cai-Yun G, Xue H et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. International Journal of Behavioral Nutrition and Physical Activity. 2018;15(1):72-.
24. Xiu-xia L, Ya Z, Yao-long C, Ke-hu Y, Zong-jiu Z. The reporting characteristics and methodological quality of Cochrane reviews about health policy research. Health policy (Amsterdam, Netherlands). 2015;119(4):503-10. doi:10.1016/j.healthpol.2014.09.002.
25. Cochrane. RevMan 5-The desktop version of the software used for editing reviews. 2020.https://community.cochrane.org/help/tools-and-software/revman-5 .
26. Jia WQ, Tian JH, Yang KH, Ma B, Liu YL, Zhang P et al. Open versus Laparoscopic Pyloromyotomy for Pyloric Stenosis: A Meta-analysis of Randomized Controlled Trials. European Journal of Pediatric Surgery. 2010.
27. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology. 2011;64(4):383-94. doi:10.1016/j.jclinepi.2010.04.026.
28. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). Journal of clinical epidemiology. 2011;64(4):407-15. doi:10.1016/j.jclinepi.2010.07.017.
29. Grant KM, Kelley SS, Smith LM, Agrawal S, Meyer JR, Romberger DJ. Bupropion and nicotine patch as smoking cessation aids in alcoholics. Alcohol (Fayetteville, NY). 2007;41(5):381-91. doi:10.1016/j.alcohol.2007.03.011.
30. Kahler CW, Cioe PA, Tzilos GK, Spillane NS, Leggio L, Ramsey SE et al. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. Alcoholism: Clinical and Experimental Research. 2017;41(6):1201-11. doi:10.1111/acer.13396.
31. O’Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM et al. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking. JAMA psychiatry. 2018;75(2). doi:10.1001/jamapsychiatry.2017.3544.
32. King A, Cao D, Vanier C, Wilcox T. Naltrexone Decreases Heavy Drinking Rates in Smoking Cessation Treatment: An Exploratory Study. Alcoholism: Clinical and Experimental Research. 2009;33(6):1044-50. doi:10.1111/j.1530-0277.2009.00925.x.
33. Fridberg DJ, Cao D, Grant JE, King AC. Naltrexone Improves Quit Rates, Attenuates Smoking Urge, and Reduces Alcohol Use in Heavy Drinking Smokers Attempting to Quit Smoking. Alcoholism: Clinical and Experimental Research. 2014;38(10):2622-9. doi:10.1111/acer.12513.
34. Anthenelli RM, Heffner JL, Wong E, Tibbs J, Russell K, Isgro M et al. A Randomized Trial Evaluating Whether Topiramate Aids Smoking Cessation and Prevents Alcohol Relapse in Recovering Alcohol-Dependent Men. Alcoholism: Clinical and Experimental Research. 2017;41(1):197-206. doi:10.1111/acer.13279.
35. Zawertailo L, Ivanova A, Ng G, Le Foll B, Selby P. Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder. Journal of clinical psychopharmacology. 2020;40(2):130-6. doi:10.1097/jcp.0000000000001172.
36. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Archives of internal medicine. 2005;165(14):1600-5. doi:10.1001/archinte.165.14.1600.
37. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. Drug and alcohol dependence. 2018;184:12-7. doi:10.1016/j.drugalcdep.2017.11.017.
38. Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. European archives of psychiatry and clinical neuroscience. 2015;265(3):259-68. doi:10.1007/s00406-014-0551-3.
39. Oon-Arom A, Likhitsathain S, Srisurapanont M. Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials. Drug and alcohol dependence. 2019;205:107631. doi:10.1016/j.drugalcdep.2019.107631.
40. Siskind DJ, Wu BT, Wong TT, Firth J, Kisely S. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis. The lancet Psychiatry. 2020;7(9):762-74. doi:10.1016/s2215-0366(20)30261-3.
41. Lotfy N, Elsawah H, Hassan M. Topiramate for smoking cessation: Systematic review and meta-analysis. Tobacco prevention & cessation. 2020;6:14. doi:10.18332/tpc/115167.
42. David SP, Chu IM, Lancaster T, Stead LF, Evins AE, Prochaska JJ. Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ open. 2014;4(3):e004393. doi:10.1136/bmjopen-2013-004393.
43. Tian J, Zhang J, Ge L, Yang K, Song F. The methodological and reporting quality of systematic reviews from China and the USA are similar. Journal of clinical epidemiology. 2017;85:50-8. doi:10.1016/j.jclinepi.2016.12.004.
44. Yao L, Sun R, Chen YL, Wang Q, Wei D, Wang X et al. The quality of evidence in Chinese meta-analyses needs to be improved. Journal of clinical epidemiology. 2016;74:73-9. doi:10.1016/j.jclinepi.2016.01.003.